202 related articles for article (PubMed ID: 18952543)
1. Considerations with newer regimens for indolent non-Hodgkin lymphoma.
Rummel M
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S128-36. PubMed ID: 18952543
[TBL] [Abstract][Full Text] [Related]
2. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
[TBL] [Abstract][Full Text] [Related]
3. What is the role of maintenance rituximab in follicular NHL?
Maloney DG
Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic advances for indolent lymphomas].
Ogura M
Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
6. Follicular lymphoma: emerging therapeutic strategies.
Kenkre VP; Kahl BS
Expert Rev Hematol; 2010 Aug; 3(4):485-95. PubMed ID: 21083037
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
[TBL] [Abstract][Full Text] [Related]
9. Primary duodenal follicular lymphoma successfully treated with rituximab.
Aguiar-Bujanda D; Quiñones-Morales I; Camacho-Galán R; Llorca-Martínez I; Rivero-Vera JC; Bohn-Sarmiento U; Aguiar-Morales J
Clin Transl Oncol; 2007 Jul; 9(7):471-2. PubMed ID: 17652063
[TBL] [Abstract][Full Text] [Related]
10. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
Seiler T; Hiddemann W; Dreyling M
Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in advanced B-cell lymphomas.
Ujjani C; Cheson BD
Oncology (Williston Park); 2010 Feb; 24(2):156-66. PubMed ID: 20361466
[TBL] [Abstract][Full Text] [Related]
12. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
[TBL] [Abstract][Full Text] [Related]
13. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
Turturro F
Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
[TBL] [Abstract][Full Text] [Related]
14. Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.
Li ZM; Ghielmini M; Moccia AA
Expert Rev Anticancer Ther; 2013 Mar; 13(3):313-25. PubMed ID: 23477518
[TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance.
Cohen Y; Solal-Céligny P; Polliack A
Haematologica; 2003 Jul; 88(7):811-23. PubMed ID: 12857561
[TBL] [Abstract][Full Text] [Related]
16. Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?
Pettengell R
Drugs; 2009; 69(13):1727-37. PubMed ID: 19719330
[TBL] [Abstract][Full Text] [Related]
17. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
18. Rituximab chemotherapy regimens for treating advanced follicular lymphoma evaluated in new study.
Askeland G
Expert Rev Clin Immunol; 2013 May; 9(5):402. PubMed ID: 23772446
[No Abstract] [Full Text] [Related]
19. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
20. New agents in follicular lymphoma.
Cheson BD
Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
